Vivos Therapeutics Receivables 2020-2025 | VVOS

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Vivos Therapeutics receivables from 2020 to 2025. Receivables can be defined as the total amount of collectibles for a company

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Vivos Therapeutics receivables from 2020 to 2025. Receivables can be defined as the total amount of collectibles for a company

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$79.5B
Zoetis (ZTS)	$68B
Daiichi Sankyo, - (DSNKY)	$46.9B
Takeda Pharmaceutical (TAK)	$46.6B
BeOne Medicines - (ONC)	$32.5B
Sandoz Group AG (SDZNY)	$26.5B
Summit Therapeutics (SMMT)	$20.5B
Merck (MKKGY)	$17.3B
Shionogi (SGIOY)	$14.6B
United Therapeutics (UTHR)	$13.8B
Neurocrine Biosciences (NBIX)	$13B
Orion OYJ (ORINY)	$11.7B
IPSEN (IPSEY)	$11.1B
Stevanato Group S.p.A (STVN)	$8.5B
Corcept Therapeutics (CORT)	$7.2B
Grifols, S.A (GRFS)	$6.8B
Ionis Pharmaceuticals (IONS)	$6.7B
Madrigal Pharmaceuticals (MDGL)	$6.6B
Hikma Pharmaceuticals Plc (HKMPF)	$6.2B
Ono Pharmaceutical (OPHLF)	$5.2B
Soleno Therapeutics (SLNO)	$4.4B
Hypermarcas (HYPMY)	$3.1B
Crinetics Pharmaceuticals (CRNX)	$2.8B
NewAmsterdam Pharma (NAMS)	$2.6B
Catalyst Pharmaceuticals (CPRX)	$2.6B
Procaps Group, S.A (PROCF)	$2.5B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.5B
Centessa Pharmaceuticals (CNTA)	$2.1B
Ocular Therapeutix (OCUL)	$1.9B
BioCryst Pharmaceuticals (BCRX)	$1.8B